| Document |
Document Title |
|
WO/2016/172001A1 |
This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of a Rac-GTPase mediated disorder (e.g., acute lymphoblastic or chronic myelogenous ...
|
|
WO/2016/164180A1 |
Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2016/161063A1 |
Provided herein are processes for the preparation of 2-thiophenecarbonyl chloride, which is useful, for example, in the preparation of 3,5-disubstituted-1,2,4-oxadiazoles, such as tioxazafen (3-phenyl-5-(2-thienyl)-1,2,4-oxadiazole).
|
|
WO/2016/155545A1 |
Disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative, a preparation method therefor, and a use thereof in pharmaceuticals. Specifically disclosed are a sulfamyl-containing 1,2,5-oxadiazole derivative of generic formula (I), a ...
|
|
WO/2016/146561A1 |
The invention relates to salts of N-(1,3,4-oxadiazol-2-yl) aryl carboxylic acid amides of general formula (I), as herbicides. In this formula (I), X, Z and R stand for groups such as hydrogen, organic groups such as alkyl, and other grou...
|
|
WO/2016/142894A1 |
The present invention relates to 3-substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an imm...
|
|
WO/2016/135062A1 |
The present invention discloses the efficient preparation of 2-substituted-4-amido-1,2,3-triazoles.
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/128541A1 |
The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.
|
|
WO/2016/113802A1 |
The present invention provides: a furoxan compound having a fluorine atom as a substituent group on the ring structure thereof; and a novel nitric oxide donor using said compound. The present invention is a fluorofuroxan compound represe...
|
|
WO/2016/112768A1 |
The present invention relates to a benzofuroxan oxide histone deacetylase inhibitor, and a preparation method therefor and uses thereof. The compound has a structure represented by a formula I or I', a tautomer II represented by the form...
|
|
WO/2016/108249A1 |
Disclosed herein are novel five membered heterocyclic compounds of Formula (I) wherein, X is S or SO2; n is 0, 1; m is1 or 2; Y is N, O or S; R2 independently represents H or alkyl or halo selected from -CI, -F; or -CF3, or -OH or-NH2 or...
|
|
WO/2016/106284A2 |
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...
|
|
WO/2016/097626A1 |
The invention relates to novel compounds, to the synthesis method thereof and to the use of same in medicine and in cosmetics. The invention relates to novel compounds, ligands that modulate RAR receptors.
|
|
WO/2016/097389A1 |
The invention relates to benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan rece...
|
|
WO/2016/094659A1 |
A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s-NH-(CH2)t, (CH2)s-0-(CH2)t, or (CH2)S-C(NH2)- (CH2)v-NH-(CH2)t,where s, t and v are each, independ...
|
|
WO/2016/093175A1 |
According to the present invention, various tri(hetero)arylacetonitrile compounds are synthesized by reacting, in the presence of a palladium catalyst, a di(hetero)arylacetonitrile compound represented by the formula: CHAr1Ar2CN (Ar1 and...
|
|
WO/2016/094729A1 |
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of G...
|
|
WO/2016/073545A1 |
This invention relates to novel phenyloxadiazole benzoic acids, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods ...
|
|
WO/2016/063990A1 |
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...
|
|
WO/2016/061344A1 |
The present invention identifies a novel class of compounds that have demonstrated activity as inhibitors of GSK3 activity. The ability to inhibit GSK3 applies to administering the compounds to subjects with identified aberrant GSK3 acti...
|
|
WO/2016/054261A1 |
Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compo...
|
|
WO/2016/046350A1 |
An organic light-emitting element which emits delayed fluorescence comprising specifically substituted 1,2,4-triazole derivatives, 1,2,4-oxadiazole derivatives or 1,2,4-thiadiazole derivatives in the light-emitting layer, a light-emittin...
|
|
WO/2016/041489A1 |
Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as an indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxyge...
|
|
WO/2016/034673A1 |
A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are ...
|
|
WO/2016/034675A1 |
A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected f...
|
|
WO/2016/034671A1 |
A compound of formula (la), (lb) or (lc) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...
|
|
WO/2016/015593A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...
|
|
WO/2016/001073A1 |
The invention relates to benzoic acid amides of general formula (I) as herbicides. In formula (I) X, Z and R represent radicals such as alkyl and cycloalkyl. Q represents a 5-membered heterocycle.
|
|
WO/2016/001074A1 |
The invention relates to benzoic acid amides of general formula (I) as herbicides. In formula (I) X, Z and R represent radicals such as alkyl and cycloalkyl. Q represents a 5-membered heterocycle.
|
|
WO/2015/196258A1 |
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosur...
|
|
WO/2015/193455A1 |
The present invention relates to the use of iminosydnone compounds in processes for the preparation of conjugates of two compounds of interest. The invention further relates to the use of said iminosydnone compounds in a process for rele...
|
|
WO/2015/188037A1 |
Provided herein are methods of treating, preventing, ameliorating or managing mucopolysaccharidosis (nmMPS) disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nmMPS. In particular, provided herein are...
|
|
WO/2015/184798A1 |
Disclosed is an N-substituted phenyl glycine (dabigatran etexilate intermediate) preparation method unreported in any document, the method comprising: utilizing cheap and easily available substituted aniline (1) as raw material to conden...
|
|
WO/2015/187827A1 |
The present invention includes compounds that are useful in preventing or treating viral infections caused by an enveloped RNA virus, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, orthomyxovirus ...
|
|
WO/2015/185485A1 |
The present invention relates to the use of novel oxadiazoles of the formula I or an N- oxide and/or their agriculturally useful salts for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful fungi, whi...
|
|
WO/2015/173419A1 |
The present invention relates to a process for the preparation of a first compound of interest C1 functionalized with a sydnone compound and to the corresponding functionalized C1 compound of interest. The present invention also relates ...
|
|
WO/2015/159103A1 |
Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are de...
|
|
WO/2015/159233A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan re...
|
|
WO/2015/157187A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2015/157382A1 |
This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for treating or preventing neurodegenerative diseases an...
|
|
WO/2015/143653A1 |
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...
|
|
WO/2015/140130A1 |
The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the d...
|
|
WO/2015/135946A1 |
Use of N-(1,3,4-Oxadiazol-2-yl)arylcarboxamides of formula (I) or salts thereof with R, X, A, and Z having the meaning as defined in the description, for controlling unwanted plants in areas of transgenic crop plants being tolerant to HP...
|
|
WO/2015/124932A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositio...
|
|
WO/2015/117912A1 |
Compounds of formula (I), wherein (II) is a five-membered, aromatic ring system which may contain 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,and where each ring system may not contain more than ...
|
|
WO/2015/116760A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1, R2a, R2b, and R3-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activi...
|
|
WO/2015/115116A1 |
Provided is an organic light emitting element which exhibits stable performance in the atmosphere. This organic light emitting element comprises a positive electrode, a negative electrode and a first organic compound layer that is arrang...
|
|
WO/2015/108038A1 |
The present invention addresses the problem of providing: a compound which is useful for the prevention or treatment of hyperphosphatemia or a hyperphosphatemia-related disease, or a pharmacologically acceptable salt of the compound; and...
|
|
WO/2015/108577A1 |
The present invention relates to 1,3,4-oxadiazole derivatives of formulae I and II, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-l-phosphate recep...
|
